Eli Lilly’s experimental oral GLP-1 receptor agonist, orforglipron, demonstrated 11.2% mean weight loss over 72 weeks in late-stage trials, falling short of higher efficacy rates observed with injectable rivals like Novo Nordisk's Wegovy. While still representing meaningful weight reduction, the oral pill’s comparatively modest performance and competition from established injectables temper its market prospects. Lilly remains optimistic about continued development for obesity and metabolic conditions, considering orforglipron's favorable safety profile and oral dosing convenience.